Cargando…

Augmented antitumor effects of erlotinib and cabozantinib on A549 non-small cell lung cancer: In vitro and in vivo studies

Non-small cell lung carcinoma is a challenging disease worldwide. This study aims to determine whether combining erlotinib, an epidermal growth factor receptor (EGFR) inhibitor, with cabozantinib, a mesenchymal-epithelial transition factor (c-Met) inhibitor, would have an augmented therapeutic benef...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alhazzani, Khalid, Alsahli, Meshal, Alanazi, Ahmed Z, Algahtani, Mohammad, Alenezi, Ahmad A, Alhoshani, Ali, Alqinyah, Mohammed, Alhamed, Abdullah S., Alhosaini, Khaled
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10495648/ https://www.ncbi.nlm.nih.gov/pubmed/37705877 http://dx.doi.org/10.1016/j.jsps.2023.101756

Ejemplares similares

Examining the Effects of Dasatinib, Sorafenib, and Nilotinib on Vascular Smooth Muscle Cells: Insights into Proliferation, Migration, and Gene Expression Dynamics
por: Alhazzani, Khalid, et al.
Publicado: (2023)

The Potential Protective Role of Naringenin against Dasatinib-Induced Hepatotoxicity
por: Alanazi, Ahmed Z., et al.
Publicado: (2023)

Gold-containing compound BDG-I inhibits the growth of A549 lung cancer cells through the deregulation of miRNA expression
por: Alhoshani, Ali, et al.
Publicado: (2018)

Protective role of Dodonaea viscosa extract against streptozotocin-induced hepatotoxicity and nephrotoxicity in rats
por: Alanazi, Ahmed Z., et al.
Publicado: (2023)

Blockade of store-operated calcium entry sensitizes breast cancer cells to cisplatin therapy via modulating inflammatory response
por: Alhamed, Abdullah S., et al.
Publicado: (2023)

Targeting Store-Operated Calcium Entry Regulates the Inflammation-Induced Proliferation and Migration of Breast Cancer Cells
por: Alqinyah, Mohammed, et al.
Publicado: (2023)

Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second- or third-line treatment of patients with EGFR wild-type advanced non-small cell lung cancer (ECOG-ACRIN 1512): a phase 2 randomised controlled trial
por: Neal, Joel W., et al.
Publicado: (2016)

Metformin attenuates V-domain Ig suppressor of T-cell activation through the aryl hydrocarbon receptor pathway in Melanoma: In Vivo and In Vitro Studies
por: Alanazi, Fawaz E., et al.
Publicado: (2022)

In vivo and in vitro studies evaluating the chemopreventive effect of metformin on the aryl hydrocarbon receptor-mediated breast carcinogenesis
por: Alhoshani, Ali, et al.
Publicado: (2021)

Involvement of the AKT Pathway in Resistance to Erlotinib and Cabozantinib in Triple-Negative Breast Cancer Cell Lines
por: Lefebvre, Cory, et al.
Publicado: (2023)

Antitumor Effect of Cabozantinib in Bone Metastatic Models of Renal Cell Carcinoma
por: Iuliani, Michele, et al.
Publicado: (2021)

Design, Synthesis, and Antitumor Activity of Erlotinib Derivatives
por: Mao, Long-fei, et al.
Publicado: (2022)

Cathepsin-B inhibitor CA-074 attenuates retinopathy and optic neuritis in experimental autoimmune encephalomyelitis induced in SJL/J mice
por: Rashid Khan, Mohammad, et al.
Publicado: (2023)

Development of a nanoliposomal formulation of erlotinib for lung cancer and in vitro/in vivo antitumoral evaluation
por: Zhou, Xiao, et al.
Publicado: (2017)

A phase Ib/II study of cabozantinib (XL184) with or without erlotinib in patients with non-small cell lung cancer
por: Wakelee, Heather A., et al.
Publicado: (2017)

Development of a Nanoliposomal Formulation of Erlotinib for Lung Cancer and in vitro/In vivo Antitumoral Evaluation [Retraction]
Publicado: (2022)

Antitumor effects of erlotinib in combination with berberine in A431 cells
por: Cuan, Xiangdan, et al.
Publicado: (2023)

Chronopharmacology and Mechanism of Antitumor Effect of Erlotinib in Lewis Tumor-Bearing Mice
por: Wang, Peipei, et al.
Publicado: (2014)

Continuous inhibition of epidermal growth factor receptor phosphorylation by erlotinib enhances antitumor activity of chemotherapy in erlotinib-resistant tumor xenografts
por: IWAI, TOSHIKI, et al.
Publicado: (2011)

Neoadjuvant cabozantinib and nivolumab convert locally advanced hepatocellular carcinoma into resectable disease with enhanced antitumor immunity
por: Ho, Won Jin, et al.
Publicado: (2021)

2-Deoxy-d-glucose Suppresses the In Vivo Antitumor Efficacy of Erlotinib in Head and Neck Squamous Cell Carcinoma Cells
por: Sobhakumari, Arya, et al.
Publicado: (2016)

In Vitro and in Vivo Antitumor Activity of Scutebarbatine A on Human Lung Carcinoma A549 Cell Lines
por: Yang, Xiao-Kun, et al.
Publicado: (2014)

Erlotinib augmentation with dapsone for rash mitigation and increased anti-cancer effectiveness
por: Kast, R. E.
Publicado: (2015)

Synthesis and Antitumor Activity of Erlotinib Derivatives Linked With 1,2,3-Triazole
por: Deng, Peng, et al.
Publicado: (2022)

Atractylenolide I inhibits EMT and enhances the antitumor effect of cabozantinib in prostate cancer via targeting Hsp27
por: Qiao, Pengfei, et al.
Publicado: (2023)

Aqueous extract of Sapindus mukorossi induced cell death of A549 cells and exhibited antitumor property in vivo
por: Liu, Min, et al.
Publicado: (2018)

Rapid modification of the bone microenvironment following short-term treatment with Cabozantinib in vivo
por: Haider, Marie-Therese, et al.
Publicado: (2015)

Effect of Autophagy Inhibitors on Radiosensitivity in DNA Repair-Proficient and -Deficient Glioma Cells
por: Saleh, Tareq, et al.
Publicado: (2022)

The glutaminase inhibitor telaglenastat enhances the antitumor activity of signal transduction inhibitors everolimus and cabozantinib in models of renal cell carcinoma
por: Emberley, Ethan, et al.
Publicado: (2021)

Development of cabozantinib for the treatment of prostate cancer
por: Vaishampayan, Ulka N
Publicado: (2014)

Cabozantinib‐induced renal thrombotic microangiopathy
por: La Manna, Gaetano, et al.
Publicado: (2017)

Cabozantinib and apixaban: an hitherto unreported interaction
por: Santini, Daniele, et al.
Publicado: (2019)

Yiqi Formula Enhances the Antitumor Effects of Erlotinib for Treatment of Triple-Negative Breast Cancer Xenografts
por: Liao, Ming-juan, et al.
Publicado: (2014)

Gefitinib and Erlotinib Lead to Phosphorylation of Eukaryotic Initiation Factor 2 Alpha Independent of Epidermal Growth Factor Receptor in A549 Cells
por: Koyama, Satoshi, et al.
Publicado: (2015)

Comparative of in-vitro Evaluation between Erlotinib Loaded Nanostructured Lipid Carriers and Liposomes against A549 Lung Cancer Cell Line
por: Abedi Gaballu, Fereydoon, et al.
Publicado: (2019)

Erlotinib-Loaded Dendrimer Nanocomposites as a Targeted Lung Cancer Chemotherapy
por: Fatani, Wafa K., et al.
Publicado: (2023)

Exposure to Methylmercury at Juvenile Stage Worsens Autism-Like Symptoms in Adult BTBR T+tf/J Mice Due to Lack of Nuclear Factor Erythroid 2-Related Factor 2 Signaling Upregulation in Periphery and Brain
por: Algahtani, Mohammad M., et al.
Publicado: (2023)

Development of cabozantinib for the treatment of prostate cancer [Corrigendum]
Publicado: (2014)

Cabozantinib for the Treatment of Metastatic Medullary Thyroid Carcinoma
por: Nix, Nancy M., et al.
Publicado: (2014)

Modulation of cabozantinib efficacy by the prostate tumor microenvironment
por: Tripathi, Manisha, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_mqsmvv5apn791f24br1qcmue76